Immunis plans Phase 1 trial of treatment for Parkinson’s dyskinesia

Immunis has recently licensed a new treatment candidate, IMM01, specifically designed to tackle levodopa-induced dyskinesia—those involuntary, jerky movements that often develop after years of using standard medication. What this means for people with the condition is a potential shift away from purely synthetic drugs toward biological therapies that aim to repair the brain's environment. To understand why this is a significant step forward, we have to look at how dyskinesia happens. While levodopa is essential for restoring dopamine and managing motor symptoms, its long-term use can lead to a "turbulent" environment in the brain. This instability often triggers inflammation and the loss of supportive structures around neurons, resulting in the erratic movements that many find just as challenging as the condition itself. The newly licensed therapy, IMM01, is a secretome-based treatment. Unlike a traditional pill, a secretome is a "cocktail" of proteins and growth factors naturally secreted by cells to promote healing and reduce inflammation. In preclinical studies, this biological mixture demonstrated an impressive ability to protect the brain's "striatum"—the area responsible for movement—and significantly reduced the severity of dyskinesia. The research suggests that this treatment works as a smarter shield. By restoring the natural balance of the brain's environment, it doesn't just mask the involuntary movements; it helps the brain tolerate levodopa more smoothly. This could mean that people can continue to benefit from their primary medication for longer periods without the debilitating side effects of dyskinesia. Immunis is now moving quickly into clinical stages, with plans to launch a Phase 1 trial later this year. This initial human study will focus on safety and finding the correct dosage, marking the first time this specific biological approach has been tested in people with the condition. By moving toward these advanced biological therapies, science is looking past a simple "band-aid" for motor issues. Instead, the focus is shifting toward precision medicine that supports the long-term health and stability of the brain's internal circuitry. This move toward protecting the "whole person" at a cellular level offers a concrete pathway for more durable care and a better quality of life for those managing the condition over many years.